TP53 and breast cancer: Other studies have suggested that significantly higher levels of immunocytes infiltrated into BC in patients with TP53 mutations compared to those with the wild-type phenotype, and TP53 mutation could promote the immunogenicity of tumors by regulating the TP53-related signaling pathways in BC (Li et al., 2019; Blagih et al., 2020).